Emerging medications in psychiatry: Transforming the treatment landscape for depression and psychosis in Parkinson’s disease

ABSTRACTIntroduction:The article reviews recent advancements in psychiatric medications for schizophrenia and depression, highlighting esketamine, and pimavanserin. It discusses their development, mechanisms, clinical efficacy, safety profiles, and future research directions, emphasizing their trans...

Full description

Saved in:
Bibliographic Details
Published in:Santosh University Journal of Health Sciences 2024-07, Vol.10 (2), p.209-219
Main Authors: Saran Brijesh, Bhagat, Tripta S, Bhagat Rohit
Format: Article
Language:English
Subjects:
Clinical outcomes
Psychosis
Schizophrenia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTIntroduction:The article reviews recent advancements in psychiatric medications for schizophrenia and depression, highlighting esketamine, and pimavanserin. It discusses their development, mechanisms, clinical efficacy, safety profiles, and future research directions, emphasizing their transformative potential and new hope for patients.Objective:The objective of this article is to review recent advancements in psychiatric medications for schizophrenia and depression, focusing on the development, pharmacological properties, clinical efficacy, safety profiles, and future directions of emerging drugs, highlighting their potential to transform treatment and improve patient outcomes.Methods:The article reviews emerging psychiatric medications, detailing their pharmacological properties, clinical efficacy, and safety profiles. It includes esketamine for treatment-resistant depression and pimavaenserin for psychosis symptoms in Parkinson’s diseases. Each drug’s mechanism of action, clinical trial results, and potential future research directions are discussed.Results:The article highlights the efficacy and safety of emerging psychiatric medications, including esketamine for treatment-resistant depression and pimavaenserin for psychosis symptoms in Parkinson’s diseases. Clinical trials demonstrate significant symptom reduction and improved patient outcomes, with ongoing research exploring further applications and optimization of these treatments.Conclusion:Emerging psychiatric medications such as esketamine and pimavenserin offer significant advancements in treating conditions such as treatment-resistant depression, postpartum depression, and schizophrenia. These drugs provide rapid and sustained symptom relief, with ongoing research aimed at optimizing their use and exploring new therapeutic applications.
ISSN:2455-1732
DOI:10.4103/sujhs.sujhs_60_24